Vaso Active: Settles SEC Fraud Charges  CHICAGO (Reuters) - Drug maker Vaso Active Pharmaceuticals  Inc. &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=VAPH.PK target=/stocks/quickinfo/fullquote"&gt;VAPH.PK&lt;/A&gt; on Thursday said U.S. regulators approved a  settlement with the company and its former chief executive over  allegedly misleading disclosures in public documents.